Although several clinical studies in patients with NSCLC have demonstrated that MET overexpression is associated with a poor survival rate [35–38], in our study, the prognostic significance of MET overexpression was only found in SCLC LD-stage patients. Here, MET is linked to non-small cell lung carcinoma.